BELLUS Health- developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. BELLUS' lead product candidate, BLU-5937, is being developed for the treatment of chronic cough (Phase II announced July 2020) and chronic pruritus (Phase II planned to begin 1H20).
BELLUS' Phase II for chronic cough, the RELIEF study is a dose-escalation, placebo-controlled, and crossover design to assess the efficacy, safety, and tolerability of BLU-5937, a highly selective P2X3 antagonist, at four doses; 25, 50, 100 and 200 mg, administered orally, twice-daily (BID). Approximately 65 patients with refractory chronic cough are expected to be enrolled at twelve clinical sites in the United Kingdom and United States.
Phase l or ll
100MM - 500MM
275 Armand-Frappier Boulevard
Laval, Quebec H7V 4A7
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Top 10 Holders of BELLUS Health Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by